Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell

Authors: Yan Zhao, Wang Jian, Wei Gao, Ya-Xin Zheng, Yong-Kun Wang, Zhu-Qing Zhou, Hui Zhang, Cong-Jun Wang

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Although much is known about both the cellular changes that lead to HCC and the etiological agents responsible for the majority of HCC cases, the molecule pathogenesis of HCC is still not well understood. We aimed to determine the effect of c-Myc gene expression on the proliferative, invasive, and migrative capabilities of hepatocellular carcinoma HepG2 cells.

Methods

A plasmid- based polymerase III promoter system was used to deliver and express short interfering RNA targeting c-Myc to reduce its expression in HepG2 cells. Western blot analysis was used to measure the protein level of c-Myc in HepG2 cells. The effects of c-Myc silencing on the invasion, motility, and proliferation of HepG2 cells were assessed using a Transwell chamber cell migration assay system and a growth curve assay, respectively.

Results

The data showed that plasmids expressing siRNA against c-Myc significantly decreased its expression in HepG2 cells by up to 85%. Importantly, pSilencer-c-Myc transfected cells showed a significantly reduced potential in migration, invasion, and proliferation.

Conclusion

C-Myc plays an important role in the development of hepatocellular carcinoma. The data show that down-regulating the c-Myc protein level in HepG2 cells by RNAi could significantly inhibit migration, invasion and proliferation of HepG2 cells. Thus, c-Myc might be a potential therapeutic target for hepatocellular carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vinay K, Abbas A, Fauston N: Robbins and Cotran pathologic basis of disease. 2004, New York: Saunders, 623-625. Vinay K, Abbas A, Fauston N: Robbins and Cotran pathologic basis of disease. 2004, New York: Saunders, 623-625.
3.
go back to reference Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002, 31 (4): 339-346. 10.1038/ng0802-339.CrossRefPubMed Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002, 31 (4): 339-346. 10.1038/ng0802-339.CrossRefPubMed
4.
go back to reference Hunecke D, Spanel R, Länger F, Nam SW, Borlak J: MYC‐regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer. J Pathol. 2012, 228 (4): 520-533.PubMed Hunecke D, Spanel R, Länger F, Nam SW, Borlak J: MYC‐regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer. J Pathol. 2012, 228 (4): 520-533.PubMed
5.
go back to reference Möröy T, Marchio A, Etiemble J, Trépo C, Tiollais P, Buendia MA: Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature. 1986, 324 (6094): 276-279. 10.1038/324276a0.CrossRefPubMed Möröy T, Marchio A, Etiemble J, Trépo C, Tiollais P, Buendia MA: Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature. 1986, 324 (6094): 276-279. 10.1038/324276a0.CrossRefPubMed
6.
go back to reference Lin CP, Liu CR, Lee CN, Chan TS, Liu HE: Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010, 2 (1): 16-PubMedCentralPubMed Lin CP, Liu CR, Lee CN, Chan TS, Liu HE: Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010, 2 (1): 16-PubMedCentralPubMed
7.
go back to reference Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, Buendia MA: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene. 1997, 14 (4): 395-10.1038/sj.onc.1200850.CrossRefPubMed Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, Buendia MA: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene. 1997, 14 (4): 395-10.1038/sj.onc.1200850.CrossRefPubMed
8.
go back to reference Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW: MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 2011, 71 (6): 2286-2297. 10.1158/0008-5472.CAN-10-3367.PubMedCentralCrossRefPubMed Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW: MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 2011, 71 (6): 2286-2297. 10.1158/0008-5472.CAN-10-3367.PubMedCentralCrossRefPubMed
9.
go back to reference Peng S, Lai P, Hsu H: Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc. 1993, 92 (10): 866-PubMed Peng S, Lai P, Hsu H: Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc. 1993, 92 (10): 866-PubMed
10.
go back to reference Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI: Modelling Myc inhibition as a cancer therapy. Nature. 2008, 455 (7213): 679-683. 10.1038/nature07260.PubMedCentralCrossRefPubMed Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI: Modelling Myc inhibition as a cancer therapy. Nature. 2008, 455 (7213): 679-683. 10.1038/nature07260.PubMedCentralCrossRefPubMed
11.
go back to reference Xu Y, Wang Y, Gao J, Ye J, Zhu H, Xu N, Wang X, Sun Z: Suppression of c-myc expression by interference RNA in HepG2 hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2004, 26: 458-460.PubMed Xu Y, Wang Y, Gao J, Ye J, Zhu H, Xu N, Wang X, Sun Z: Suppression of c-myc expression by interference RNA in HepG2 hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2004, 26: 458-460.PubMed
12.
go back to reference Gearhart J, Pashos EE, Prasad MK: Pluripotency redux—advances in stem-cell research. N Engl J Med. 2007, 357 (15): 1469-1472. 10.1056/NEJMp078126.CrossRefPubMed Gearhart J, Pashos EE, Prasad MK: Pluripotency redux—advances in stem-cell research. N Engl J Med. 2007, 357 (15): 1469-1472. 10.1056/NEJMp078126.CrossRefPubMed
13.
go back to reference Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS: N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 2008, 68 (23): 9654-10.1158/0008-5472.CAN-08-1961.PubMedCentralCrossRefPubMed Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS: N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 2008, 68 (23): 9654-10.1158/0008-5472.CAN-08-1961.PubMedCentralCrossRefPubMed
14.
go back to reference Chiu YL, Ali A, Chu C, Cao H, Rana TM: Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004, 11 (8): 1165-1175. 10.1016/j.chembiol.2004.06.006.CrossRefPubMed Chiu YL, Ali A, Chu C, Cao H, Rana TM: Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004, 11 (8): 1165-1175. 10.1016/j.chembiol.2004.06.006.CrossRefPubMed
15.
go back to reference Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007, 6 (7): 556-568. 10.1038/nrd2355.CrossRefPubMed Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007, 6 (7): 556-568. 10.1038/nrd2355.CrossRefPubMed
16.
go back to reference Yan B, Wang ZH, Guo JT: The research strategies for probing the function of long noncoding RNAs. Genomics. 2011, 99 (2): 76-80.CrossRefPubMed Yan B, Wang ZH, Guo JT: The research strategies for probing the function of long noncoding RNAs. Genomics. 2011, 99 (2): 76-80.CrossRefPubMed
17.
go back to reference Dykxhoorn DM, Novina CD, Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003, 4 (12): 7-17. Dykxhoorn DM, Novina CD, Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003, 4 (12): 7-17.
18.
go back to reference Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001, 411 (6836): 494-498. 10.1038/35078107.CrossRefPubMed Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001, 411 (6836): 494-498. 10.1038/35078107.CrossRefPubMed
19.
go back to reference Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001, 98 (17): 9742-9747. 10.1073/pnas.171251798.PubMedCentralCrossRefPubMed Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001, 98 (17): 9742-9747. 10.1073/pnas.171251798.PubMedCentralCrossRefPubMed
20.
go back to reference Niu XY, Peng ZL, Duan WQ, Wang H, Wang P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006, 16 (2): 743-751. 10.1111/j.1525-1438.2006.00384.x.CrossRefPubMed Niu XY, Peng ZL, Duan WQ, Wang H, Wang P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006, 16 (2): 743-751. 10.1111/j.1525-1438.2006.00384.x.CrossRefPubMed
21.
go back to reference Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003, 9 (3): 931-946.PubMed Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res. 2003, 9 (3): 931-946.PubMed
Metadata
Title
RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell
Authors
Yan Zhao
Wang Jian
Wei Gao
Ya-Xin Zheng
Yong-Kun Wang
Zhu-Qing Zhou
Hui Zhang
Cong-Jun Wang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-23

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine